01 7Bevespi
02 5Breztri
03 2Lonhala Magnair
04 6Seebri Breezhaler
05 2Ultibro Breezhaler
06 3Ultibro Group
Budesonide, Glycopyrronium and Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 28
2019 Revenue in Millions : 2
Growth (%) : 1,300
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 22
2019 Revenue in Millions : 17
Growth (%) : 28
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 48
2019 Revenue in Millions : 42
Growth (%) : 14
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 623
2019 Revenue in Millions : 630
Growth (%) : -1
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 54
2020 Revenue in Millions : 48
Growth (%) : 13
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 203
2020 Revenue in Millions : 28
Growth (%) : 625
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 584
2020 Revenue in Millions : 623
Growth (%) : -6
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 479
2021 Revenue in Millions : 584
Growth (%) : -18
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 58
2021 Revenue in Millions : 54
Growth (%) : 7
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 398
2021 Revenue in Millions : 203
Growth (%) : 96
LOOKING FOR A SUPPLIER?